The present status and future prospects of peptide-based cancer vaccines.
about
Identification of the core regulators of the HLA I-peptide binding processEfficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma.DNA vaccine with discontinuous T-cell epitope insertions into HSP65 scaffold as a potential means to improve immunogenicity of multi-epitope Mycobacterium tuberculosis vaccine.Immunotherapy of colorectal cancer: new perspectives after a long path.Applications of Immunogenomics to Cancer.Personalized peptide vaccines and their relation to other therapies in urological cancer.Engineering of a self-adjuvanted iTEP-delivered CTL vaccine.From the era of ineffective tumor vaccines to a future with effective immunotherapy.Deep Omics.Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Vaccination in the immunotherapy of glioblastoma.Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine.Present status and future perspective of peptide-based vaccine therapy for urological cancer.Nanomaterials for cancer immunotherapy.Targeting Head and Neck Cancer by Vaccination.Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson's disease.Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity.Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor ProgressionTrial watch: DNA-based vaccines for oncological indicationsNext Generation Cancer Vaccines-Make It Personal!
P2860
Q29048598-2DB4FF0B-FEF5-44A2-892A-A04862F34A86Q37477273-2126261C-E88F-49A1-8369-2E0CA5F877EAQ38751464-1BDF31C3-E40D-4961-B73C-1B618049789AQ39043413-92FE088B-EFC1-4A5B-8750-C6CCD84275CFQ39130420-DDBE1BC6-35C0-40D1-99C6-271155332AFEQ39340541-6B4F5779-5318-4F4E-8C83-CAE31C140911Q40248942-7005B180-C410-4BAF-83A4-01B7337D754FQ42331951-8476F69B-05EE-44AC-909A-E0ED69320838Q47295103-6A838DEF-1180-4534-A199-7CE252C4555BQ47406496-C8A1C36A-5945-4797-AFA4-777D115B5302Q47583155-A8FC7481-BF3E-4ECA-B88E-134F7B597535Q47629539-94FF45BC-99E4-4585-9F44-2B41624AF19AQ47725715-BE71DDAA-6472-4178-9B82-6E2F64EBBE28Q48646732-50F45925-563E-4AFF-89B8-CCB8D97886BCQ54217605-27743E17-C314-4970-9298-0F6812DF3C10Q54959442-E45180A4-6508-47FC-9613-EB4226AC5D9EQ55291915-81780668-086F-4A0B-967F-4DBF25420B72Q56889963-C277E914-59FB-423D-BE13-46C6D56BA97DQ56893452-2C2A6DD0-D12E-4992-BE08-3F8B1F41D0E6Q58791982-C6CC1722-E54C-44B7-9235-F583C0CEFC0E
P2860
The present status and future prospects of peptide-based cancer vaccines.
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
The present status and future prospects of peptide-based cancer vaccines.
@ast
The present status and future prospects of peptide-based cancer vaccines.
@en
The present status and future prospects of peptide-based cancer vaccines.
@nl
type
label
The present status and future prospects of peptide-based cancer vaccines.
@ast
The present status and future prospects of peptide-based cancer vaccines.
@en
The present status and future prospects of peptide-based cancer vaccines.
@nl
prefLabel
The present status and future prospects of peptide-based cancer vaccines.
@ast
The present status and future prospects of peptide-based cancer vaccines.
@en
The present status and future prospects of peptide-based cancer vaccines.
@nl
P2860
P356
P1476
The present status and future prospects of peptide-based cancer vaccines.
@en
P2093
Masatoshi Hirayama
Yasuharu Nishimura
P2860
P304
P356
10.1093/INTIMM/DXW027
P577
2016-05-28T00:00:00Z